Join Growin Stock Community!

Senti biosciences, inc.SNTI.US Overview

US StockHealthcare
(No presentation for SNTI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SNTI AI Insights

SNTI Overall Performance

SNTI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SNTI Recent Performance

-2.54%

Senti biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SNTI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SNTI Key Information

SNTI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SNTI Profile

Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.

Price of SNTI

SNTI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SNTI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.81
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
55.46
PB Ratio
3.18
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.81
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
55.46
PB Ratio
3.18
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is SNTI's latest earnings report released?

    The most recent financial report for Senti biosciences, inc. (SNTI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SNTI's short-term business performance and financial health. For the latest updates on SNTI's earnings releases, visit this page regularly.

  • How much debt does SNTI have?

    As of the end of the reporting period, Senti biosciences, inc. (SNTI) had total debt of 30.12M, with a debt ratio of 0.57. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SNTI have?

    At the end of the period, Senti biosciences, inc. (SNTI) held Total Cash and Cash Equivalents of 15.78M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SNTI's EPS continuing to grow?

    According to the past four quarterly reports, Senti biosciences, inc. (SNTI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.69. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SNTI?

    Senti biosciences, inc. (SNTI)'s Free Cash Flow (FCF) for the period is -9.45M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 21.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SNTI?

    The latest valuation data shows Senti biosciences, inc. (SNTI) has a Price-To-Earnings (PE) ratio of -0.99 and a Price/Earnings-To-Growth (PEG) ratio of -0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.